

Diabetes Australia Research Trust 2012 Grant Round

Viertel Fellowship Award

Dr Karly Sourris

Baker IDI Heart and Diabetes Institute

Type 1 & Type 2

Interactions between glucagon like peptide (GLP-1) and the receptor for advanced glycation end products (RAGE) in the development and progression of diabetic nephropathy.

Underworks Millennium Type 2 Award

Professor Julie Owens

University of Adelaide

Type 2

Identifying epigenetic pathways from maternal obesity to type 2 diabetes in offspring

Millennium Type 1 Award

Dr Cecile King

Garvan Institute

Type 1

Interleukin-21 as a therapeutic target in type 1 diabetes

General Grants

Professor Paul McMenanim

Monash University

Type 1 and Type 2

The role of resident corneal immune cells in the development of diabetes associated corneal neuropathy

Dr Antonia Miller

Monash University

Type 1 and Type 2

Evaluation the molecular detail of epigenetic memory in diabetic retinopathy

Associate Professor Matthew Watt

Monash University

Type 2

Does lipid accumulation in hypothalamic neurons contribute to the development of whole-body insulin resistance?

Dr Elizabeth Barr

Baker IDI Heart and Diabetes Institute

Type 2

Improving the prediction of diabetes and cardiovascular disease in urban Indigenous Australians: follow-up of the DRUID study cohort

Associate Professor Leonie Heilbronn

University of Adelaide

Type 2

Does Hyperbaric Oxygen Therapy Modulate Insulin Resistance?

Professor Jennifer Wilkinson-Berka

Monash University

Type 1 and Type 2

The contribution of NADPH oxidase and microglia to diabetic retinopathy

Associate Professor Mark Gorrell

Centenary Institute

Type 2 and Complications

Targeting proteases for a novel therapy for type 2 diabetes and liver complications

Dr Phillip Kantharidis

Baker IDI Heart and Diabetes Institute

Type1 and Type 2

The microRNA-29 is a regulator of diabetic renal fibrosis

Dr Paul Gregorevic

Baker IDI Heart and Diabetes Institute

Type1 and Gestational

Evaluating follistatin as a novel therapeutic for diabetes, and for diabetic complications

Associate Professor Sofianos Andrikopoulos

University of Melbourne

Type 1

Targeted treatment for fibrosis with FT61 will improve renal and heart function in experimental model of diabetic nephropathy and cardiomyopathy

Dr Martha Lappas

University of Melbourne

Gestational

Does the maternal environment contribute to fetal overgrowth in women with gestational diabetes?

Professor Joseph Proietto

University of Melbourne

Type 1

Obesity in older adults with diabetes: effect of exercise and weight loss on physiology and function.

Dr David Stapelton

University of Melbourne

Type 2

Molecular basis for impaired hepatic glycogen metabolism in Type 2 diabetes

Professor Jennifer Couper

University of Adelaide

Type 1

Does Metformin improve vascular health in overweight youth with type 1 diabetes?

Associate Professor Rebecca Ritchie

Baker IDI Heart and Diabetes Institute

Type 1

The novel HNO donor 1-nitrosocyclohexyl acetate (1-NCA) blocks diabetes – induced cardiac dysfunction

Dr Yeesim Khew-Goodall

University of Adelaide

Type 2

A novel regulator of insulin-stimulated glucose uptake

Professor Margaret Morris

University of Adelaide

Type 2

How does early life stress (ELS) increase risk of metabolic disease and diabetes? Role of subsequent high fat diet (HFD) consumption, and stress later in life

Dr Sheila Patel

University of Melbourne

Type 2

The genetic influences on cardiac hypertrophy in type 2 diabetes

Dr John Wentworth

Walter and Eliza Hall Institute

Type 2 and Obesity

Lipid-induced inflammation and human insulin resistance

Dr Matthew Linden

RMIT University

Type 2

Using Evidence to Guide Treatment of Aspirin Resistance in Diabetes

Dr Myra Poon

The Children's Hospital at Westmead

Type 1

The role of environmental factors in the development of microvascular and macrovascular complications in type 1 diabetes – A 14 year follow-up of an incident cohort

Dr Yinghua Yu

University of Wollongong

Type 2

How do distinct fatty acids affect central leptin sensitivity and glucose intolerance in obesity and Type II diabetes?

Professor Michael Davies

University of Sydney

Type 1 and Type 2

Role of high glucose in cellular dysfunction and cardiovascular disease in people with diabetes

Associate Professor Duncan Campbell

St Vincent's Institute

Type 2

Mechanisms of diabetic cardiomyopathy

Dr Itamar Levinger

Victoria University

Type 2

Does undercarboxylated osteocalcin involved in increase insulin-stimulated skeletal muscle glucose uptake following muscle contraction?

Dr Georgia Frangioudakis

Garvan Institute

Type 2

Adjustment of sphingolipid metabolism to enhance insulin action

Dr Lisa Moran

University of Adelaide

Type 2

Lifestyle interventions during pregnancy to reduce type 2 diabetes mellitus in overweight and obese women

Associate Professor John Whitehead

Mater Medical Research Institute

Type 2

Characterising a novel adipogenic pathway to identify new therapeutic targets for obesity related diabetes

Professor Mark Febbraio

Baker IDI Heart and Diabetes Institute

Type 2

Effect of adipose tissue specific deletion of Interleukin 6 on insulin sensitivity

Dr Morton Burt

Flinders University

Other

Effect of therapeutic glucocorticoids on insulin sensitivity, cardiovascular risk and energy metabolism in patients with inflammatory arthritis

Dr Nigel Turner

Garvan Institute

Type 2

Regulation of mitochondrial function and insulin action in skeletal muscle by lysine acetylation

Dr Kristine McGrath

University of Sydney

Type 2

Can HDL mimetics be used as a therapeutic option to restore insulin sensitivity?

Dr Xiaoyu Wang

University of Sydney

Type 2

Incretins as Therapy in Diabetic Cardiomyopathy

Dr Elke Sokoya

Flinders University

Other

Novel mechanisms underlying cerebral vascular dysfunction in metabolic syndrome

Professor Karin Jandeleit-Dahm

Baker IDI Heart and Diabetes Institute

Type 1

Targeting a new microRNA in diabetes associated atherosclerosis and restenosis

Professor Ann Simpson

University of Technology

Type 1

Gene and stem cell therapy for diabetes mellitus

Dr Carsten Schmitz-Peiffer

Garvan Institute

Type 2

The role of branched chain amino acid degradation in the improvement of glucose homeostasis caused by protein kinase C epsilon deletion

Dr Virginie Lecomte

University of NSW

Type 1 and Type 2

Effect of paternal obesity on insulin sensitivity and glucose tolerance of offspring

Professor George Muscat

University of Queensland

Type 2

The nuclear receptor, RorY, and the regulation of skeletal muscle insulin sensitivity

Dr Kathryn Backholer

Baker IDI Heart and Diabetes Institute

Type 2

Long-term population health impact of type 2 diabetes screening and prevention strategies among Australian adults

Behavioural General Grant Award

Dr Jennifer Wong

Monash University

Type 2

Improving the metabolic health of patients treated with Clozapine, an atypical antipsychotic.

Professor Brian Oldenburg

Monash University

Type 2

The process of care in managing people with type 2 diabetes: What is the impact of peer support on uptake and effective implementation of care plans in the self-management of diabetes?

Professor Stephen Colagiuri

University of Sydney

Type 2 and other

Long-term follow up of the Sydney Diabetes Prevention Program (SDPP) cohort